If -blocker is contraindicated, a non-DHP CCB can be substituted, but not if left ventricular dysfunction or HF is present. Caution should be exercised if combining a non-DHP CCB with a -blocker. Esmolol (intravenous) or metoprolol or bisoprolol (oral). Spironolactone or eplerenone if left ventricular dysfunction, HF, or diabetes mellitus is present. Carvedilol, metoprolol succinate, or bisoprolol. Table 3. Summary of BP Goals BP Goal, mmHg Condition Class/Level of Evidence <140/90 CAD IIa/B ACS IIa/C HF IIa/B <130/80 CAD IIb/B Post myocardial infarction, stroke or TIA, carotid artery disease, PAD, AAA IIb/B AAA indicates abdominal aortic aneurysm; ACS, acute coronary syndrome; BP, blood pressure; CAD, coronary artery disease; HF, heart failure; PAD, peripheral arterial disease; and TIA, transient ischemic attack. Rosendorff et al Treatment of Hypertension in Patients With CAD 1377 determine the appropriate intensity of statin therapy to reduce CVD risk in those most likely to benefit. Those patients with CVD and age 75 years, with LDL cholesterol 190 mg/dL, or with a 10-year CVD risk 7.5% should receive high- intensity statin therapy (eg, atorvastatin 40 80 mg/d or rosuvastatin 20 40 mg/d to reduce LDL cholesterol by approximately 50%). Those with CVD who are >75 years of age or those with diabetes mellitus but with a 10-year risk of <7.5% should receive moderate-intensity statin therapy such as simvastatin 20 to 40 mg/d, atorvastatin 10 to 20 mg/d, or rosuvastatin 5 to 10 mg/d to decrease LDL cholesterol by 30% to 50%. According to the guideline, nonstatin therapies do not provide acceptable CVD risk reduction benefits compared with their potential for adverse effects in the routine prevention of CVD. 1.1.5. 